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Abstract: Trypanosoma rangeli and T. cruzi are both parasitic unicellular species that infect humans. Unlike T. cruzi, 
the causative agent of Chagas disease, T. rangeli is an infective and non-pathogenic parasite for humans, but pathogenic 
for vectors from the Rhodnius genus. Because both species can coexist in different hosts and overlap their infective 
cycles but very little is known about the infection of T. rangeli in mammalian cells, we decided to characterize both the 
development of this parasite in cell culture and the effect of therapeutic agents with potential trypanocidal action on 
it. We found that T. rangeli exhibits a cycle of infection in Vero cells similar to that for T. cruzi and that the repurposed 
drug, 17-AAG, and the natural extract Artemisia sp. essential oil produce a toxic effect on epimastigotes showing 
a trypanocidal action from the fifth day of culture. Both treatments also affected the infection of trypomastigotes 
and reduced the capacity of replication of amastigotes of T. rangeli. Since T. cruzi / T. rangeli coinfection cases have 
been reported, the finding of drugs with potential activity against both species could be significant in the future. 
Furthermore, studies of susceptibility of both species to drugs could also help to know the different mechanisms of 
pathogenicity in humans displayed by T. cruzi that are absent in T. rangeli.
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Introduction
Tr y panosoma rangeli is a protozoan parasite that infects 
mammals and triatomines, causing different levels of 
pathogenicity in its invertebrate vectors, particularly those 
from the genus Rhodnius (Ferreira et al., 2018; Grewal, 1957; 
Añez et al., 1985). Unlike T. cruzi, the causative agent of 
Chagas disease, T. rangeli infects humans without causing 
pathologies.
Morphologically corresponds to a trypanosome that 
measures about 31 µm in length and has a more developed 
undulating membrane than T. cruzi. Its kinetoplast is 
subterminal and small, features that allow its morphological 
differentiation with T. cruzi.
The development of T. rangeli in triatomine insects 
begins when the trypomastigote forms are ingested with 
the blood of infected mammals. When these forms reach 
*Address correspondence to: María Cristina Vanrell,
vanrellcristina@gmail.com
 the midgut of the vector (hemolymph), they differentiate 
into epimastigotes that become capable of replicating. After 
10 to 15 days they invade the salivary glands, where they 
differentiate into metacyclic trypomastigotes. Rounded forms 
are also found as well as short and long epimastigotes, which 
can be transformed into trypomastigotes in the hindgut 
(D’Alessandro and Hincapie, 1986). After inoculation of 
man, the parasites enter the circulation (Urdaneta-Morales 
and Tejero, 1985). Some groups have shown the presence of 
amastigote nests in tissues (Urdaneta-Morales and Tejero, 
1985; Osorio et al., 1995; Eger-Mangrich et al., 2001), while 
others have not observed them (Tanoura et al., 1999).
The majority of reported human cases of T. rangeli 
infections correspond to Venezuela, Colombia, Paraná, 
Guatemala, El Salvador and Brazil. The laboratory procedures 
used for the diagnosis are based on the direct search, in fresh 
or stained material, which serves for the morphological 
study. Its differential diagnosis is important, because T. 
rangeli and T. cruzi can coexist, producing mixed infections. 
More specific methods, including immunofluorescence, 
immunoprecipitation and ELISA techniques, have been used 
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to confirm T. rangeli misdiagnosed infections (Hudson et 
al., 1988) Norte de Santander, Columbia (n = 327. Recently, 
a conventional PCR and a loop-mediated isothermal 
amplification (LAMP) assay were developed to differentiate T. 
rangeli and T. cruzi in samples extracted from the vector bugs 
(Thekisoe et al., 2010).
Regarding treatment little is known about the performance 
of drugs with trypanocidal action. The first report of drug 
test on T. rangeli was that of nifurtimox (Lampit) in infected 
mice (Marinkelle, 1982). The ability of 54 different derivatives 
of pyrazolo[3,4-d]- or pyrazolo[4,3-d]-pyrimidine have 
also been studied to inhibit the multiplication of T. rangeli 
forms in culture. Among them, 4-aminopyrazolo-[3,4-d]-
pyrimidine (APP) is the most active (Avila et al., 1981). Growth 
inhibitory effects of six guanine and guanosine analogs, 
3-desazaguanine; 3-deazaguanosine; 6-aminoallopurinol; 
9-beta-xylofuranosyl guanine; a ribosyl derivative of the 
compound 3,6-aminopyrazolo[3,4-d]-pyrimidin-4-one; and 
5-aminoformycin B, have also been tested against T. rangeli (Avila 
et al., 1987). Idarubicin (a topoisomerase inhibitor) has shown a 
promising trypanocidal activity with a maximum mean growth 
inhibition value in the submicromolar range (Jobe et al., 2012).
The main objective of this work was to characterize the 
in vitro development of T. rangeli at different times of its 
life cycle; mainly at the time of infection of trypomastigotes 
into mammalian cells, and the time of the intracellular 
replication of amastigotes. Additionaly, we studied the 
possible effect of potential trypanocidal compounds on the 
different stages of T. rangeli cycle.
Two classes of treatments were studied: (1) the geldanamycin 
derivative 17-(allylamino)-17-demethoxygeldanamycin (17-
AAG), a drug used in the treatment of certain classes of cancers, 
and (2) the Artemisia sp. (Asterales, Asteraceae) essential oil. The 
first one is the less toxic analog of geldanamycin and a potent 
inhibitor of heat shock protein 90 (Hsp90). It was the first Hsp90 
inhibitor to enter clinical trials as an antineoplastic drug due to its 
significant anti-tumor activity (Jhaveri et al., 2014); 17-AAG was 
repurposed as a drug against Leishmania spp. (Kinetoplastida, 
Trypanosomatidae), because of its demonstrated in vitro and in 
vivo action on this parasite (Petersen et al., 2012), and we thought 
it could also have trypanocidal activity on T. rangeli. We also 
explored the action of Artemisia essential oil because there was 
evidence of its action against T. brucei, T. cruzi and T. congolense 
(Naß and Efferth, 2018)the safety and efficacy of current synthetic 
drugs are limited due to the development of drug resistance and 
adverse side effects. PURPOSE Artemisia annua and artemisinin 
are not only active against Plasmodia, but also other protozoa. 
Therefore, we reviewed the literature on species of the genus 
Artemisia and their phytochemicals regarding their activity 
against trypanosomes. STUDY DESIGN A PubMed search 
for \”Artemisia/Artemisinin and Trypanosoma\” has been 
conducted for literature until December 2017. RESULTS 
Interestingly, not only A. annua L. and its active principle, 
artemisinin revealed inhibitory activity towards trypanosomes. 
Other Artemisia species (A. absinthium, A. abyssinica, A. afra, 
A. douglasia, A. elegantissima, A. maciverae, A. mexicana, and 
A. roxburghiana). It has also been proposed as a therapeutic 
agent in malaria (Pellicer et al., 2018).
Material and Methods
Reagents
The Diamond medium contains 6.25 g/l tryptose (Sigma), 
6.25 g/l tryptone (Sigma), 6.25 g/l yeast extract (Sigma), 
7.16 g/l KH2PO4 (Biopack) (pH 7.2) and 6.66 mM hemin 
(Calbiochem) prepared in 3 ml of 1N NaOH (Tetrahedron) 
and 20 ml of 1M Tris/HCl  (Tetrahedron) (pH 6.8).
Mammalian cells culture
Epithelial cells (Vero cell line) were grown in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 
10% fetal bovine serum (FBS) and antibiotics at 37°C in an 
atmosphere of 5% CO2.
Epimastigotes
We used the LDG (Colombian) strain of T. rangeli . 
Epimastigotes of T. rangeli were cultured in Diamond 
medium with 10% fetal bovine serum (Natocor) at 28°C. The 
culture contain hemin (20 mg/l), 10% inactivated fetal bovine 
serum, and streptomycin (100 mg / ml; Gibco) and penicillin 
(100 U / ml; Gibco).
Trypomastigotes
T. rangeli trypomastigotes (LDG Colombian strain) were 
obtained by in vitro metacyclogenesis of epimastigotes, as 
described elsewhere (Contreras et al., 1986), and maintained 
in a culture of Vero cells in DMEM supplemented with 3% 
FBS and antibiotics at 37°C in an atmosphere of 5% CO2.
AlamarBlue assay
Cell viability was estimated by the AlamarBlue assay 
(Invitrogen), according to the manufacturer’s instructions. 
Vero cells grown in 96-well plates were washed three times 
with PBS and incubated in control medium (DMSO) in 
presence or absence of 0.1 µM 17-AAG and 0.5 μg / ml 
Artemisia essential oil (stalks, leaves, and flowers, were 
distilled in water steam stills for extracting the essence) at 
37ºC for 24 h. After that, cells were washed and 10% of the 
AlamarBlue reagent was added to the medium and incubated 
for 6 h at 37ºC before measurement of absorbance at 540 nm.
Growth of epimastigotes
We started with a solution of 1 × 106 epimastigotes per 
milliliter in control (DMSO), 0.1 µM 17-AAG and 0.5 μg / 
ml Artemisia essential oil condition. Then, we counted the 
epimastigotes at different times, using a Neubauer chamber.
T. rangeli infection assays on Vero cells
We collected the trypomastigotes from the infected Vero cell 
cultures, by centrifugating samples for 15 min at 4000 rpm. The 
supernatant was discarded and 1 ml of fresh medium was added. 
Two hous later, we collected the supernatant rich in swimming 
trypomastigotes. We then treated the trypomastigotes with 
control medium (DMSO), 0.1 µM 17-AAG and 0.5 μg / ml 
Artemisia essential oil for 30 min before seeding them on 
Vero cell monolayers, at a proportion of 10 parasites per cell. 
After 24 h, the cells were washed with PBS, fixed with 4% 
paraformaldehyde, quenched with 50 mM ammonium chloride 
and mounted with Mowiol containing Hoechst. The percentage 
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of infected cell was quantified by confocal microscopy using a 
FV1000 Confocal Olympus microscope.
Growth of amastigotes
Vero cells were infected with T. rangeli tripomastigotes for 
24 hours, then they were washed with PBS to eliminate 
the trypomastigotes that did not infect and fresh medium 
was placed in control condition (DMSO), 0.1 µM 17-AAG 
and 0.5 μg / ml Artemisia essential oil for additional 24 h. 
Then the cells were fixed with 4% paraformaldehyde for 15 
min, quenched with 50 mM ammonium chloride for 15 
min, treated with albumin saponin for 20 min, and then 
the amastigotes were detected by immunoluorescence. The 
number of parasites in each cell was quantified by confocal 
microscopy using a FV1000 Confocal Olympus microscope.
statistics
Multigroup comparisons were made by ANOVA followed by 
the Tukey test (using Kyplot®).
Results
T. rangeli infection course in Vero cells
As mentioned above, we wanted to study the capacity of T. 
rangeli to infect and to develop into mammalian cells. To 
asses this, we performed an in vitro assay using Vero cells as 
host cells. These kidney-derived epithelial cells are broadly 
used for growing viruses and eukaryotic parasites, especially 
the trypanosomatids. We also used these cells to generate 
the parasites used for infection assays. In the experiment, 
cells were incubated in the presence of trypomastigotes of T. 
rangeli (MOI = 10) for 24 h (interaction period) and, after 
washing, they were fixed and stained with the DNA marker 
Hoechst 33342 for microscopy analysis. Other samples were 
washed and incubated in medium without parasites for an 
additional time of 24 h before fixation (chase period) and 
then processed as described before (Fig. 1A). Microscopy 
studies showed the presence of parasite nuclei and 
kinetoplasts inside Vero cells after 24 h incubation (Fig. 1B). 
Interestingly, samples maintained for 48 h showed a higher 
number of amastigote-like parasites surrounding Vero cell 
nuclei (Fig. 1C), denoting that parasites can replicate inside 
the cells. Quantitative data showed that more than 50% of 
cells became infected after 24 h of interaction (Fig. 3D) and 
approximately 10 amastigote-like parasites/cell developed 
at 48 h (Fig. 4C). Seven to 10 days after interaction, new 
trypomastigotes were released into the culture medium 
(data not shown), indicating that T. rangeli had completed its 
intracellular cycle by this time. Taking together, these results 
revealed that T. rangeli can infect and replicate in mammalian 
cells and that its intracellular cycle can be studied in vitro. 
FIGURE 1. T. rangeli infection and replication in epithelial cells in vitro. 
Interaction of trypomastigotes of T. rangeli with Vero cells were 
evaluated by adding trypomastigotes (MOI = 10) to cell monolayers 
for 24 h (interaction period) before washing and fixation. Other 
samples were washed and left for additional 24 h to evaluate the 
replication of amastigotes (chase period). After fixation, both 
samples were stained with Hoechst 33342 to label kinetoplast DNA 
from parasites and nuclear DNA from parasites and host cells. (A) 
Experimental scheme. (B) Images show Vero cells infected with T. 
rangeli after the interaction period. The nuclei of Vero cells and the 
nuclei and kinetoplasts of T. rangeli are labeled in blue. (C) Images 
show amastigotes generated in the host cytoplasm during the chase 
period. All cell nuclei are shown in blue. Scale bar: 10 µm.
FIGURE 2. Effect of drugs on the growth of epimastigotes of T. rangeli. 
We started with a culture of 1 × 106 T. rangeli epimastigotes /ml in 
Diamond medium under control conditions (with DMSO), 0.1 μM 
17-AAG and 0.5 μg / ml Artemisia essential oil. A small aliquot of 
each sample was taken on days 3, 5, and 10 to quantify the number 
of parasites by counting them in a Neubauer chamber. The graph 
shows the mean ± SE of each treatment at the different times.
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FIGURE 3. Effect of drugs on T. rangeli infection of epithelial cells. First, 
we evaluated the cell viability by the AlamarBlue test. Vero cells 
grown in 96-well plates were incubated in control medium in the 
presence or absence of 0.1 μM 17-AAG and 0.5 μg / ml Artemisia 
essential oil at 37°C for 24 h. After washing, the AlamarBlue 
reagent was added to each sample and incubated for 6 h at 37°C 
before absorbance measurement at 540 nm. Cell growth, based on 
the detection of cell metabolic activity, was proportional to these 
value. In other set of experiments, trypomastigotes were incubated 
in control condition (DMSO), 0.1 μM 17-AAG and 0.5 μg / ml 
Artemisia essential oil for 30 min at 37°C. After that, parasites were 
placed on Vero cell monolayers for 24 h before washing and fixation. 
(A) The graph indicates the mean ± SE of absorbances at 540 nm at 
the different conditions. (B) Scheme of the infection experiment. (C) 
Images show the level of infection under the different treatments. 
Scale bar: 10 µm. (D) Percentage of infected cells. Bars show the 
mean ± SE of two independent experiments. Tukey test ** P < 0.01.
17-AAG and Artemisia essential oil affected the growth and 
caused death on epimastigotes of T. rangeli
Next we studied the effect of the two potential trypanocidal 
treatments on the different stages of the T. rangeli life 
cycle. Initially, we analyzed the action of treatments on 
axenic epimastigote cultures, by incubating the parasites in 
Diamond medium alone (control) or supplemented with 
0.1 µM 17-AAG and 0.5 µg / ml Artemisia essential oil for 
10 days. We selected these concentrations from previously 
published works, which have shown the effect of these 
compounds on other trypanosomatids (Santos et al., 2014; 
Pellicer et al., 2018). The number of parasites counted at 
different times of incubation showed that epimastigotes 
increased exponentially in the control condition from day 0 
to 10 (Fig. 2). No significant differences were observed in the 
17-AAG and Artemisia essential oil conditions at the initial 
times of growth compared to controls. Interestingly, from 
the fifth day both 17-AAG and Artemisia essential oil curves 
decreased and reached to value 0 on day 10. These data 
suggest a trypanocidal action of both treatments from this 
day onwards.
17-AAG and Artemisia essential oil reduce the infective 
capacity of trypomastigotes of T. rangeli
Since those results were encouraging, we decided to test the 
effect of both treatments on the infective forms of T. rangeli. 
To control for a possible toxic effect of compounds on Vero 
cells, we subjected cells to the treatments for 24 h at 37°C and 
then analyzed cell viability using the AlamarBlue assay. Both 
17-AAG and Artemisia essential oil did not affect cell viability 
(Fig. 3A). Next, we tested the effects of these compounds 
on trypomastigote-infected Vero cells. For such purpose, T. 
rangeli trypomastigotes were exposed to control medium (with 
DMSO), 0.1 μM 17-AAG or 0.5 μg / ml Artemisia essential 
oil for 30 min and then placed on Vero cell monolayers for 24 
h in the same conditions (Fig. 3B). After fixation, we stained 
with the fluorescent DNA dye, Hoechst, as explained above, 
to evaluate the level of host cell infection. As shown in the 
images depicted in Figure 3C the amount of parasites in cells 
was lower under both treatments than in control cells., The 
percentage of infected cells was, in consequence, significantly 
reduced at these conditions compared to cells under control 
medium (Fig. 3D). We concluded that both drugs significantly 
reduced the infective capacity of trypomastigotes of T. rangeli, 
having 17-AAG a more marked effect.
17-AAG and Artemisia essential oil affect replication of 
amastigotes of T. rangeli long after infection
Next we analyzed the effect of treatments on amastigote 
replication. Vero cell monolayers were infected with 
trypomastigotes of T. rangeli (MOI = 10) for 24 h. Then they were 
washed to eliminate free trypomastigotes and incubated in control 
(DMSO), 0.1 μM 17-AAG and 0.5 μg / ml Artemisia essential 
oil conditions for a chase period of 24 h (Fig. 4A). After fixation, 
samples were subjected to an indirect immunofluorescence 
method to detect the parasites. Remarkably, we observed that 
samples treated with 17-AAG and Artemisia essential oil displayed 
a fewer number of amastigote-like forms than that in controls 
(Fig. 4B). Further quantification showed an important reduction 
in the number of amastigotes per cell as compared to controls, 
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indicating that both treatments affect amastigote replication of T. 
rangeli (Fig. 4C).
FIGURE 4. Effect of drugs on the growth of T. rangeli amastigotes. Vero 
cells were infected with trypomastigotes at a ratio of 10 parasites per 
cell for 24 h, and then were washed and incubated for an additional 
period of 24 h in control condition (DMSO), 0.1 μM 17-AAG or 0.5 
μg / ml Artemisia essential oil at 37°C. (A) Experimental scheme. 
(B) Images show the level of replication of amastigotes under the 
different treatments. Scale bar: 10 µm. (C) Quantification of the 
number of amastigotes per cell. Bars show the mean ± SE of two 
independent experiments. 
Discussion
The main interest in the study of Trypanosoma rangeli, 
a trypanosomatid initially described by Tejera in 1920 
(Borzone et al., 1950), is that it has the same geographical 
distribution, is frequently transmitted by the same vectors, 
and infects the same vertebrates as T. cruzi, the etiologic 
agent of Chagas disease. This explains the number of 
morphological, biochemical and molecular studies pursuing 
its differentiation from T. cruzi, which have been based 
in the morphology and DNA of kinetoplasts, the electron 
microscopy study of epimastigotes in many trypanosomatid 
species under standardized conditions (Mühlpfordt, 1975), 
the identification of carbohydrates as beta-D-galactose and 
alpha or beta-N-acetyl-D-galactosamine on the cell surface 
(Marinkelle et al., 1986; Chung et al., 2003; Bretting and 
Schottelius, 1978; González et al., 1996; de Miranda Santos 
and Pereira, 1984), and the isoenzyme patterns (Kreutzer 
and Sousa, 1981; Tibayrenc and Le Ray, 1984). The use of 
restriction enzymes that divide the mini circles of DNA of 
the kinetoplast in its variable region (Frasch et al., 1981) 
and the amplification of the mini-exon gene repeated in 
tandem (Murthy et al., 1992) or DNA fingerprints (Pires et 
al., 2008) are also some of the molecular methods that make 
possible the differentiation of T. cruzi from T. rangeli. Some 
metabolic differences between both species have also been 
observed (Avila et al., 1981; Nosei and Avila, 1985; Holguín 
et al., 1987), as well as the resistance of epimastigotes to 
lysis by serum (Schottelius, 1982; Marinkelle et al., 1986). 
Regarding infection and intracellular cycle in mammalian 
cells, this study showed that T. rangeli shows a behavior 
similar to T. cruzi. We observed that trypomastigotes of T. 
rangeli can infect cells, replicate intracellularly as amastigote-
like forms and exit the cells as trypomastigotes. Although we 
have not studied the complete intracellular cycle displayed 
by T. rangeli, our observations suggest that this parasite can 
differentiate from trypomastigote to amastigote-like forms 
and viceversa. More experiments will be needed to elucidate 
the mechanisms implicated in these processes.
There is controversy about the course of infection of T. 
rangeli in vertebrate hosts. The first case of human infection 
was discovered in Brazil (de Lucena and Marques, 1954). In 
white male NMRI mice, a high (up to 7 times the original 
inoculum in the peak) and persistent parasitemia (for up 
to 2 weeks) have been observed (Urdaneta-Morales and 
Tejero, 1985). The parasites disappeared completely from the 
circulation after 20-25 days. Using a similar infection model, 
these and other authors have also observed numerous nests 
or intracellular pseudocysts containing amastigotes and 
trypomastigotes in the heart, liver, and spleen ( Scorza et al., 
1986; Urdaneta-Morales and Tejero, 1985; Osorio et al., 1995; 
Eger-Mangrich et al., 2001). The above characteristics, as 
well as the location of the pseudocysts in tissues, are similar 
to those of T. cruzi. However, there are other works in which 
the histological examination could not detect any form of T. 
rangeli in several organs of mice (Tanoura et al., 1999). Our in 
vitro results tend to support the findings of the first group of 
authors, because of the intracellular formation of amastigote 
nests in cultured cells.
It is interesting to observe that, among the trypanosomes 
that can infect humans, T. cruzi seems to be pathogenic 
for vertebrates but not for invertebrates (Chagas, 1909), 
whereas on the contrary, T. rangeli seems to be pathogenic for 
invertebrates but not for vertebrates (Tejera, 1920). Moreover, 
it has been demonstrated that both trypanosomatid species 
can coexists in the host (Araújo et al., 2013) mixed infections 
and their consequences for the host’s health and parasite 
transmission are still a poorly known phenomenon. The 
mini-exon multiplex PCR characterization detected the 
infection by T. rangeli and T. cruzi (TcI genotype and 
even this coinfection could be benefitial for them. New 
investigations are needed to clarify these aspects.
Considering the similar intracellular cycle of T. rangeli 
as compared with that of T. cruzi, as well as the non-
pathogenic profile of this parasite, we next focused our study 
to the analysis of the effect of two new treatments against T. 
rangeli that could be tested against T. cruzi in the future. We 
used 17-AAG, a repurposed drug that were fistly used in the 
therapy against cancer (Menden et al., 2018), and with good 
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results in the treatment of Leishmania infections (Petersen et 
al., 2018; Santos et al., 2014; Petersen et al., 2012). Our data 
showed that 17-AAG was effective to reduce the infection 
of trypomastigotes on Vero cells and the replication of 
epimastigotes and amastigotes. Similar results were obtained 
with the Artemisia essential oil, although this extract could 
show toxic effects at large doses and after prolonged periods 
of treatment (Ribnicky et al., 2004) a common medicinal and 
culinary herb with centuries of use. Artemisia dracunculus 
is a close relative of the French or cooking tarragon and 
contains components common to many herbs that are 
routinely consumed without reported adverse effects. Since 
safety information of Artemisia dracunculus and its extract 
is limited to historical use, TARRALIN was examined in a 
series of toxicological studies. Complete Ames analysis did 
not reveal any mutagenic activity either with or without 
metabolic activation. TARRALIN was tested in an acute 
limit test at 5000 mg/kg with no signs of toxicity noted. In 
a 14 day repeated dose oral toxicity study, rats appeared to 
well tolerate 1000 mg/kg/day. Subsequently, TARRALIN was 
tested in an oral subchronic 90-day toxicity study (rat. This 
is why we are interested in testing the effect of the specific 
component, artemisinin, which is effective in the treatment 
of malaria and is not toxic (Desrosiers and Weathers, 2016).
We consider that our work makes a contribution in the 
field of therapies against trypanosomatid parasites. Future 
experiments will be conducted with T. cruzi to confirm the 
possible antichagasic action of these treatments. Furthermore, 
the comparative study of these therapies on both species 
could be useful to elucidate the mechanisms for the different 
pathogenicity of them in vertebrate and invertebrate hosts.
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